$0.56
27.56%
Nasdaq, Sep 21, 01:49 pm EDT. Market open.
ISIN
US60855D1019
Symbol
MBRX

Moleculin Biotech, Inc. Stock price

$0.77
+0.16 26.72% 1M
-1.31 62.83% 6M
-2.54 76.64% YTD
-9.53 92.49% 1Y
-143.60 99.46% 3Y
-1,094.23 99.93% 5Y
-13,409.23 99.99% 10Y
-17,999.23 100.00% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.01 0.88%
ISIN
US60855D1019
Symbol
MBRX
Industry

Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$15.1m
Enterprise Value
$7.8m
Net debt
positive
Cash
$7.3m
Shares outstanding
7.1m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
67.8%
Return on Equity
-224.3%
ROCE
-245.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-28.8m
EBIT
$-28.9m
Net Income
$-32.5m
Free Cash Flow
$-25.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-13.9%
EBIT
-13.5%
Net Income
-22.5%
Free Cash Flow
-18.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-5.7
FCF per Share
$-3.6
Short interest
0.9%
Employees
17
Rev per Employee
$0.0

Moleculin Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Moleculin Biotech, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Moleculin Biotech, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Moleculin Biotech, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.15 9.15
3% 3%
-
- Research and Development Expense 20 20
20% 20%
-
-29 -29
14% 14%
-
- Depreciation and Amortization 0.05 0.05
58% 58%
-
EBIT (Operating Income) EBIT -29 -29
13% 13%
-
Net Profit -33 -33
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moleculin Biotech, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
Neutral
GlobeNewsWire
10 days ago
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
Neutral
GlobeNewsWire
25 days ago
- Video webcast now available here
More Moleculin Biotech, Inc. News

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Head office United States
CEO Mr. Klemp
Employees 17
Founded 2015
Website moleculin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today